{"id":"metformin-gliclazide","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Hypoglycemia"},{"rate":"10-20","effect":"Gastrointestinal disturbance (nausea, diarrhea, abdominal pain)"},{"rate":"5-10","effect":"Headache"},{"rate":"3-8","effect":"Dizziness"},{"rate":"<0.1","effect":"Lactic acidosis (rare)"}]},"_chembl":{"chemblId":"CHEMBL427216","moleculeType":"Small molecule","molecularWeight":"323.42"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metformin decreases hepatic glucose production and improves peripheral insulin sensitivity, while gliclazide stimulates pancreatic beta cells to increase insulin secretion. Together, they address both insulin resistance and beta-cell dysfunction in type 2 diabetes through complementary mechanisms.","oneSentence":"This combination reduces blood glucose by increasing insulin secretion and improving insulin sensitivity in type 2 diabetes patients.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:34.274Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT02879409","phase":"NA","title":"HbA1c Variability in Type II Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Cornell Medical College in Qatar","startDate":"2016-11","conditions":"Diabetes Mellitus Type 2","enrollment":150},{"nctId":"NCT06085703","phase":"NA","title":"Effects of Henagliflozin on the Brain Function in T2DM Patients With Mild Cognitive Impairment: a Randomized, Parallel Controlled Clinical Trial","status":"COMPLETED","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-04-01","conditions":"Type 2 Diabetes Mellitus, Mild Cognitive Impairment","enrollment":24},{"nctId":"NCT06613854","phase":"PHASE4","title":"Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes","status":"RECRUITING","sponsor":"University Medical Centre Ljubljana","startDate":"2024-10-01","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":90},{"nctId":"NCT06613750","phase":"PHASE4","title":"Comparative Study of Sitagliptin and Gliclazide With Metformin in Type 2 Diabetes Patients With Glucotoxicity","status":"COMPLETED","sponsor":"Zhibin Xu","startDate":"2024-06-01","conditions":"Type 2 Diabetes Mellitus, Glucotoxicity","enrollment":129},{"nctId":"NCT06570980","phase":"","title":"Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.","status":"RECRUITING","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2023-08-25","conditions":"Type 2 Diabetes Mellitus (T2DM), Cost-effectiveness, Sulfonylureas, DPP4 Inhibitors, Metformin","enrollment":200},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT05284344","phase":"","title":"The Impact of Glucotoxicity on Gastric Emptying in Chinese Patients With Newly Diagnosed Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Adelaide","startDate":"2021-01-24","conditions":"Type 2 Diabetes","enrollment":78},{"nctId":"NCT06222476","phase":"NA","title":"Effect of Dorzagliatin on Renal Function Outcomes in People With Type 2 Diabetes: a Multicentric, Prospective, Randomized Study.","status":"NOT_YET_RECRUITING","sponsor":"Yan Bi","startDate":"2024-02-20","conditions":"Diabetic Nephropathy Type 2","enrollment":106},{"nctId":"NCT06217887","phase":"NA","title":"Efficacy Comparison of Polyethylene Glycol Loxenatide and Gliclazide on the Brain Function in T2DM Patients","status":"UNKNOWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2020-05-10","conditions":"Type 2 Diabetes Mellitus, Cognitive Function Abnormal","enrollment":58},{"nctId":"NCT03076112","phase":"PHASE3","title":"Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2017-04-25","conditions":"Type 2 Diabetes Mellitus","enrollment":170},{"nctId":"NCT01131182","phase":"PHASE4","title":"Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-13","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":1147},{"nctId":"NCT04192292","phase":"NA","title":"Study of Sulphonylurea Synergy With DPP4 Inhibitors","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2019-10-08","conditions":"Type 2 Diabetes","enrollment":30},{"nctId":"NCT03819790","phase":"PHASE4","title":"The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians","status":"COMPLETED","sponsor":"LMC Diabetes & Endocrinology Ltd.","startDate":"2018-10-02","conditions":"Diabetes Mellitus, Type 2","enrollment":119},{"nctId":"NCT00102466","phase":"PHASE3","title":"Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-01","conditions":"Diabetes Mellitus, Type 2","enrollment":1007},{"nctId":"NCT02682563","phase":"PHASE4","title":"Renoprotective Effects of Dapagliflozin in Type 2 Diabetes","status":"COMPLETED","sponsor":"M.H.H. Kramer","startDate":"2016-02","conditions":"Diabetes Mellitus, Type 2, Diabetic Nephropathies","enrollment":44},{"nctId":"NCT02694263","phase":"PHASE4","title":"Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2016-07","conditions":"Diabetes Mellitus, Type 2","enrollment":25},{"nctId":"NCT03467945","phase":"PHASE1","title":"Bioequivalence and Drug - Drug Interaction Study of Metformin/Gliclazide in Healthy Participants","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2018-02-16","conditions":"Healthy","enrollment":40},{"nctId":"NCT03467971","phase":"PHASE1","title":"A Study to Assess the Food Effect on Bioavailability of Metformin/Gliclazide in Healthy Participants","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2018-03-06","conditions":"Healthy","enrollment":21},{"nctId":"NCT01697592","phase":"PHASE3","title":"Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-24","conditions":"Type 2 Diabetes Mellitus","enrollment":585},{"nctId":"NCT01709305","phase":"PHASE4","title":"A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-11-08","conditions":"Type 2 Diabetes Mellitus","enrollment":5570},{"nctId":"NCT01590771","phase":"PHASE3","title":"A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-07-09","conditions":"Type 2 Diabetes Mellitus","enrollment":498},{"nctId":"NCT03196154","phase":"","title":"Association Between Insulin Resistance and Beta Cell Function With HbA1C in Diabetics","status":"COMPLETED","sponsor":"Clinical Research Centre, Malaysia","startDate":"2017-08-01","conditions":"Diabetes Mellitus, Type 2","enrollment":255},{"nctId":"NCT00780715","phase":"PHASE4","title":"Response To Oral Agents in Diabetes (ROAD)- Pilot Study","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2008-12","conditions":"Diabetes Mellitus, Type 2","enrollment":29},{"nctId":"NCT01340768","phase":"PHASE3","title":"Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-22","conditions":"Type 2 Diabetes Mellitus","enrollment":870},{"nctId":"NCT01076075","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-03","conditions":"Type 2 Diabetes Mellitus","enrollment":427},{"nctId":"NCT01357135","phase":"","title":"An Observational Study of Type II Diabetics Treated With Dual Therapy With or Without Sitagliptin (Januvia®/Xelevia®, MK-0431-201)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-07-15","conditions":"Type 2 Diabetes Mellitus","enrollment":3453},{"nctId":"NCT03125694","phase":"PHASE3","title":"Sitagliptin vs. Pioglitazone as add-on Treatments in Patients With Type 2 Diabetes Uncontrolled on the Full-dose Metformin Plus Sulfonylurea","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2015-02-01","conditions":"Uncontrolled Type 2 Diabetes Mellitus","enrollment":250},{"nctId":"NCT01798706","phase":"PHASE3","title":"Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-06","conditions":"Type 2 Diabetes","enrollment":350},{"nctId":"NCT00379769","phase":"PHASE3","title":"RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2001-04","conditions":"Diabetes Mellitus, Type 2","enrollment":4447},{"nctId":"NCT03068065","phase":"PHASE4","title":"Antidiabetic Effects on Intrahepatic Fat","status":"COMPLETED","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2014-05","conditions":"Non-Alcoholic Fatty Liver Disease, Type2 Diabetes","enrollment":87},{"nctId":"NCT02476760","phase":"","title":"Incretin-based Drugs and Acute Pancreatitis","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":1417914},{"nctId":"NCT01944618","phase":"","title":"forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP)","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2013-10","conditions":"Type 2 Diabetes","enrollment":5000},{"nctId":"NCT02456428","phase":"","title":"Incretin-based Drugs and the Risk of Heart Failure","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Type 2 Diabetes Mellitus","enrollment":1499650},{"nctId":"NCT02475499","phase":"","title":"Incretin-based Drugs and Pancreatic Cancer","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":886172},{"nctId":"NCT02587741","phase":"EARLY_PHASE1","title":"Comparison of Diabetes Retinopathy Among Type 2 Diabetic Patients Treated With Different Regimens","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2015-07","conditions":"Diabetic Retinopathy","enrollment":600},{"nctId":"NCT00700856","phase":"PHASE4","title":"Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents.Intervention Trial","status":"UNKNOWN","sponsor":"Italian Society of Diabetology","startDate":"2008-09","conditions":"Type 2 Diabetes Mellitus, Cardiovascular Disease","enrollment":3371},{"nctId":"NCT01269996","phase":"PHASE4","title":"JanUmet Before Insulin Lantus In Eastern Population Evaluation Program (JUBILEE) In Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2011-05","conditions":"Type 2 Diabetes Mellitus","enrollment":71},{"nctId":"NCT02526810","phase":"PHASE4","title":"Comparison of Glycaemic Fluctuation and Oxidative Stress Between Two Short-term Therapies for Type 2 Diabetes","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2015-07","conditions":"Diabetes Mellitus, Type 2","enrollment":70},{"nctId":"NCT01584232","phase":"PHASE3","title":"A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-04","conditions":"Type 2 Diabetes Mellitus","enrollment":361},{"nctId":"NCT01195259","phase":"","title":"Malignancy Meta Analysis for BRL49653","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10","conditions":"Diabetes Mellitus, Type 2","enrollment":1},{"nctId":"NCT01758380","phase":"PHASE4","title":"Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-01","conditions":"Type 2 Diabetes Mellitus","enrollment":557},{"nctId":"NCT01963130","phase":"","title":"Does Vildagliptin Affect Portal Vein Pressure In Patients With Type 2 Diabetes Mellitus? A Cross Sectional Study","status":"COMPLETED","sponsor":"Bezmialem Vakif University","startDate":"2012-07","conditions":"Drug Mechanism, Drug Usage","enrollment":97},{"nctId":"NCT00506194","phase":"NA","title":"Short-Term Intensive Insulin Therapy Induction of Long-term Glycemic Control","status":"COMPLETED","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2005-10","conditions":"Type 2 Diabetes","enrollment":60},{"nctId":"NCT00978263","phase":"NA","title":"Comparison of Glargine and Oral Antidiabetic Drugs (OADs) in Newly Diagnosed Type 2 Diabetes","status":"COMPLETED","sponsor":"Chongqing Medical University","startDate":"2009-02","conditions":"Diabetes","enrollment":47},{"nctId":"NCT01771185","phase":"NA","title":"Metabolic Effects of Gastrointestinal Surgery in T2DM","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2012-10","conditions":"Type 2 Diabetes","enrollment":24},{"nctId":"NCT01420692","phase":"NA","title":"The Effects of Insulin Detemir and Gliclazide-MR Treatments on Endothelial Functions in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Ankara University","startDate":"2010-06","conditions":"Type 2 Diabetes Mellitus","enrollment":64},{"nctId":"NCT01426737","phase":"PHASE4","title":"The Swiss Glucose Variability Study","status":"UNKNOWN","sponsor":"University of Zurich","startDate":"2011-04","conditions":"Type 2 Diabetes","enrollment":50},{"nctId":"NCT00367055","phase":"PHASE4","title":"Rosiglitazone-Metformin Combination Versus Metformin-Sulfonylurea Combination On Beta-Cell Function In Type 2 Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-10","conditions":"Type 2 Diabetes Mellitus","enrollment":84},{"nctId":"NCT00347100","phase":"PHASE4","title":"Insulin Glargine in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-06","conditions":"Diabetes Mellitus, Type 2","enrollment":387},{"nctId":"NCT00147836","phase":"NA","title":"Evaluation of the Effects of Different Interventions on Glycemic Control in Newly-Diagnosed Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2004-09","conditions":"Type 2 Diabetes Mellitus","enrollment":436},{"nctId":"NCT00169624","phase":"PHASE3","title":"Peripheral and Coronary Endothelial Dysfunction In Type 2diabetic Patients- Role of Metformin","status":"TERMINATED","sponsor":"Hospices Civils de Lyon","startDate":"2005-10","conditions":"Coronary and Peripheral Endothelial Dysfunction","enrollment":30},{"nctId":"NCT00464594","phase":"NA","title":"Japan Early Diabetes Intervention Study","status":"UNKNOWN","sponsor":"Japan Early Diabetes Intervention Study Group","startDate":"2007-04","conditions":"Diabetes Mellitus","enrollment":2560}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["rosiglitazone-metformin","Metformin"],"phase":"marketed","status":"active","brandName":"metformin+ gliclazide","genericName":"metformin+ gliclazide","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination reduces blood glucose by increasing insulin secretion and improving insulin sensitivity in type 2 diabetes patients. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}